What is claimed is:

1. An isolated human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, wherein the antibody or antigen binding fragment thereof is an isotype other than an IgA isotype.

2. The isolated human monoclonal antibody or antigen-binding fragment thereof of claim 1 having an isotype selected from the group consisting of an IgG1, an IgG2 and an IgG4.

3. The isolated human monoclonal antibody or antigen-binding fragment thereof of claim 1 or 2, wherein the human antibody or antigen-binding fragment thereof binds specifically to Fel d1 with a K_D equal to or less than 10^{-6} M, as measured by surface plasmon resonance.

4. The isolated human monoclonal antibody or antigen-binding fragment thereof of any of claims 1-3, wherein the antibody comprises the three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) contained within any one of the heavy chain variable region (HCVR) sequences selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322, 338, 354 and 370; and the three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within any one of the light chain variable region (LCVR) sequences selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362 and 378.

5. The isolated human monoclonal antibody or antigen-binding fragment thereof of any of claims 1-4, comprising a HCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322, 338, 354 and 370.

6. The isolated human monoclonal antibody or antigen-binding fragment thereof of any of claims 1-5, comprising a LCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362 and 378.

7. The isolated human monoclonal antibody or antigen-binding fragment thereof of any one of claims 1-6, comprising: (a) a HCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242,

258, 274, 290, 306, 322, 338, 354 and 370; and (b) a LCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362 and 378.

8. The isolated human monoclonal antibody or antigen-binding fragment thereof of any one of claims 1-7, comprising:

(a) a HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 228, 244, 260, 276, 292, 308, 324, 340, 356 and 372;

(b) a HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 22, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 230, 246, 262, 278, 294, 310, 326, 342, 358 and 374;

(c) a HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 232,248, 264, 280, 296, 312, 328, 344, 360 and 376;

(d) a LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 220, 236, 252, 268, 284, 300, 316, 332, 348, 364 and 380;

(e) a LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 222, 238, 254, 270, 286, 302, 318, 334, 350, 366 and 382; and

(f) a LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, 240, 256, 272, 288, 304, 320, 336, 352, 368 and 384.

9. The isolated human monoclonal antibody or antigen-binding fragment of any one of claims 1-8, comprising a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346, 354/362 and 370/378.

10. The isolated human monoclonal antibody of any of claims 1 through 9, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with at least one amino acid sequence selected from group consisting of amino acid residues ranging from about position 15 to about position 24 of SEQ ID NO: 396; amino acid residues ranging from about position 85 to about position 103 of SEQ ID NO: 396; amino acid residues ranging from about position 85 to about

position 104 of SEQ ID NO: 396; and amino acid residues ranging from about position 113 to about position 127 of SEQ ID NO: 396.

11. The isolated human monoclonal antibody of claim 10, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with amino acid residues ranging from about position 15 to about position 24 of SEQ ID NO: 396.

12. The isolated human monoclonal antibody of claim 10, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with amino acid residues ranging from about position 85 to about position 103 of SEQ ID NO: 396.

13. The isolated human monoclonal antibody of claim 10, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with amino acid residues ranging from about position 85 to about position 104 of SEQ ID NO: 396.

14. The isolated human monoclonal antibody of claim 10, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with amino acid residues ranging from about position 113 to about position 127 of SEQ ID NO: 396.

15. The isolated human monoclonal antibody of any of claims 1 through 10, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 402, 403, 404 and 412.

16. The isolated human monoclonal antibody of claim 15, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with SEQ ID NO: 402.

17. The isolated human monoclonal antibody of claim 15, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with SEQ ID NO: 403.

18. The isolated human monoclonal antibody of claim 15, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with SEQ ID NO: 404.

19. The isolated human monoclonal antibody of claim 15, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with SEQ ID NO: 412.

20. A pharmaceutical composition comprising a therapeutically effective amount of one or more isolated human monoclonal antibodies, or antigen-binding fragments thereof, of any of claims 1-19, which bind specifically to Fel d1, together with one or more pharmaceutically acceptable excipients.

21. A pharmaceutical composition comprising a therapeutically effective amount of a first isolated human monoclonal antibody, or an antigen-binding fragment thereof that binds specifically to Fel d1; and a second isolated human monoclonal antibody, or an antigen-binding fragment thereof that binds specifically to Fel d1, of any of claims 1-19, together with one or more pharmaceutically acceptable excipients.

22. The pharmaceutical composition of claim 21, wherein:

a) the isolated first human monoclonal antibody, or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR having an amino acid sequence as set forth in SEQ ID NO: 18; and a LCVR having an amino acid sequence as set forth in SEQ ID NO: 26; and

b) the isolated second human monoclonal antibody, or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 66, 130, 162, 306, 322 and 370; and a LCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 74, 138, 170, 314, 330 and 378.

23. The pharmaceutical composition of claim 21, wherein:

a) the isolated first human monoclonal antibody, or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR having an amino acid sequence as set forth in SEQ ID NO: 242; and a LCVR having an amino acid sequence as set forth in SEQ ID NO: 250; and

b) the isolated second human monoclonal antibody, or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 306 and 322; and a LCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 314 and 330.

24. The pharmaceutical composition of claim 21, wherein:

a) the isolated first human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR/LCVR amino acid sequence pair consisting of SEQ ID NOs: 18/26; and

b) the isolated second human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 66/74, 130/138, 162/170, 306/314, 322/330 and 370/378.

25. The pharmaceutical composition of claim 21, wherein:

a) the isolated first human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR/LCVR amino acid sequence pair consisting of SEQ ID NOs: 18/26; and

b) the isolated second human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR/LCVR amino acid sequence pair consisting of SEQ ID NOs: 130/138.

26. The pharmaceutical composition of claim 21, wherein:

a) the isolated first human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR/LCVR amino acid sequence pair consisting of SEQ ID NOs: 18/26; and

b) the isolated second human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR/LCVR amino acid sequence pair consisting of SEQ ID NOs: 322/330.

27. The pharmaceutical composition of claim 21, wherein:

a) the isolated first human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR/LCVR amino acid sequence pair consisting of SEQ ID NOs: 18/26; and

b) the isolated second human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR/LCVR amino acid sequence pair consisting of SEQ ID NOs: 306/314.

28. The pharmaceutical composition of claim 21, wherein:

a) the isolated first human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR/LCVR amino acid sequence pair consisting of SEQ ID NOs: 18/26; and

b) the isolated second human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR/LCVR amino acid sequence pair consisting of SEQ ID NOs: 370/378.

29. The pharmaceutical composition of claim 21, wherein:

a) the isolated first human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR/LCVR amino acid sequence pair consisting of SEQ ID NOs: 242/250; and

b) the isolated second human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 306/314 and 322/330.

30. The pharmaceutical composition of claim 21, wherein:

a) the isolated first human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR/LCVR amino acid sequence pair consisting of SEQ ID NOs: 242/250; and

b) the isolated second human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR/LCVR amino acid sequence pair consisting of SEQ ID NOs: 306/314.

31. The pharmaceutical composition of claim 21, wherein:

a) the isolated first human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR/LCVR amino acid sequence pair consisting of SEQ ID NOs: 242/250; and

b) the isolated second human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises a HCVR/LCVR amino acid sequence pair consisting of SEQ ID NOs: 322/330.

32. The pharmaceutical composition of claim 20, comprising four isolated human monoclonal antibodies that bind specifically to Fel d1, or antigen-binding fragments thereof, wherein the human antibodies or antigen-binding fragments thereof comprise the HCVR/LCVR amino acid sequence pairs of SEQ ID NOs: 18/26, 66/74, 130/138 and 162/170.

33. An isolated antibody or antigen-binding fragment thereof that competes for specific binding to Fel d1 with an antibody or antigen-binding fragment comprising the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR), wherein the HCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322, 338, 354 and 370; and the CDRs of a light chain variable region (LCVR), wherein the LCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362 and 378.

34. An isolated antibody or antigen-binding fragment thereof that binds the same epitope on Fel d1 as an antibody or antigen-binding fragment comprising the complementarity determining regions

(CDRs) of a heavy chain variable region (HCVR), wherein the HCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322, 338, 354 and 370; and the CDRs of a light chain variable region (LCVR), wherein the LCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362 and 378.

35. A nucleic acid molecule encoding a human monoclonal antibody, or a fragment thereof that binds specifically to Fel d1 according to any one of claims 1-19, or claims 33-34.

36. An expression vector comprising the nucleic acid molecule encoding a human monoclonal antibody, or a fragment thereof that binds specifically to Fel d1 according to claim 35.

37. A host cell containing the expression vector of claim 36.

38. A bi-specific antigen-binding molecule that specifically binds Fel d1, comprising a first antigen-binding domain that comprises a HCVR amino acid sequence as set forth in SEQ ID NO: 370 and a LCVR amino acid sequence as set forth in SEQ ID NO: 378, and a second antigen-binding domain that comprises a HCVR amino acid sequence as set forth in SEQ ID NO: 18 and a LCVR amino acid sequence as set forth in SEQ ID NO: 378.

39. The bi-specific antigen-binding molecule of claim 38, wherein the first antigen-binding domain comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) consisting of the amino acid sequences as set forth in SEQ ID NOs: 372, 374 and 376, respectively, and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) consisting of the amino acid sequences as set forth in SEQ ID NOs: 380, 382 and 384, respectively; and wherein the second antigen-binding domain comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) consisting of the amino acid sequences as set forth in SEQ ID NOs: 20, 22 and 24, respectively, and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) consisting of the amino acid sequences as set forth in SEQ ID NOs: 380, 382 and 384, respectively.

40. A bi-specific antigen-binding molecule that specifically binds Fel d1, comprising a first antigen-binding domain that comprises a HCVR amino acid sequence as set forth in SEQ ID NO: 306 and a LCVR amino acid sequence as set forth in SEQ ID NO: 314, and a second antigen-

binding domain that comprises a HCVR amino acid sequence as set forth in SEQ ID NO: 18 and a LCVR amino acid sequence as set forth in SEQ ID NO: 314.

41. The bi-specific antigen-binding molecule of claim 40, wherein the first antigen-binding domain comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) consisting of the amino acid sequences as set forth in SEQ ID NOs: 308, 310 and 312, respectively, and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) consisting of the amino acid sequences as set forth in SEQ ID NOs: 316, 318 and 320, respectively; and wherein the second antigen-binding domain comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) consisting of the amino acid sequences as set forth in SEQ ID NOs: 20, 22 and 24, respectively, and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) consisting of the amino acid sequences as set forth in SEQ ID NOs: 316, 318 and 320, respectively.

42. An isolated antibody specific for Fel d1, or an antigen-binding fragment thereof, that competes for binding to Fel d1 with the bi-specific antigen-binding molecule of any of claims 38 to 41.

43. An isolated antibody specific for Fel d1, or an antigen-binding fragment thereof, that binds to the same epitope on Fel d1 as the bi-specific antigen-binding molecule of any of claims 38 to 41.

44. The isolated antibody of either claim 42 or 43, wherein the antibody is a mono-specific antibody or a bi-specific antibody.

45. A pharmaceutical composition comprising a bi-specific antigen-binding molecule of any one of claims 38 to 41 and a pharmaceutically acceptable carrier or diluent.

46. A method for treating a patient who demonstrates a sensitivity to, or an allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein, or for treating at least one symptom or complication associated with a sensitivity to, or allergic reaction against a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein, comprising administering an effective amount of one or more isolated human monoclonal antibodies or antigen-binding fragments thereof that bind specifically to Fel d1, according to any of claims 1-19, or 33-34; or a pharmaceutical composition comprising an effective amount of one or more isolated human monoclonal antibodies or fragments thereof that bind specifically to Fel d1 according to any of claims 20-32; or an effective amount of one or more of the bi-specific antigen-binding molecules of any one of claims 38-41; or a pharmaceutical composition comprising an effective amount of one or more of the bi-specific

antigen-binding molecules of any one of claims 38-41, to a patient in need thereof, wherein the sensitivity to, or an allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein is either prevented, or lessened in severity and/or duration, or at least one symptom or complication associated with the sensitivity to, or allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein is prevented, or ameliorated, or that the frequency and/or duration of, or the severity of the sensitivity to or allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein is reduced following administration of one or more of the isolated human monoclonal antibodies or fragments thereof that bind specifically to Fel d1, or following administration of one or more of the bi-specific antigen-binding molecules that specifically binds Fel d1, or following administration of a composition comprising any one or more of the foregoing antibodies or bi-specific antigen-binding molecules.

47. The method of claim 46, further comprising administering an effective amount of a second therapeutic agent useful for diminishing an allergic reaction to a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein.

48. The method of claim 47, wherein the second therapeutic agent is selected from the group consisting of a corticosteroid, a bronchial dilator, an antihistamine, epinephrine, a decongestant, another different antibody to Fel d1 and a peptide vaccine.

49. The method of any one of claims 46 to 48, wherein the treatment results in a reduction in allergic rhinitis, allergic conjunctivitis, allergic asthma, or an anaphylactic response following exposure of the patient to a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein.

50. The pharmaceutical composition of any of claims 20-32, or 45 for use in treating a patient who demonstrates a sensitivity to, or an allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein, or for treating at least one symptom or complication associated with a sensitivity to, or allergic reaction against a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein, wherein the sensitivity to, or an allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein is either prevented, or lessened in severity and/or duration, or at least one symptom or complication associated with the sensitivity to, or allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein is prevented, or ameliorated, or that the frequency and/or duration of, or the severity of the sensitivity to or allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein is reduced.

51. Use of the pharmaceutical composition of any one of claims 20-32, or 45 in the manufacture of a medicament for use in treating a patient who demonstrates a sensitivity to, or an allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein, or for treating at least one symptom or complication associated with a sensitivity to, or allergic reaction against a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein, wherein the sensitivity to, or an allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein is either prevented, or lessened in severity and/or duration, or at least one symptom or complication associated with the sensitivity to, or allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein is prevented, or ameliorated, or that the frequency and/or duration of, or the severity of the sensitivity to or allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein is reduced.

52. Use of the pharmaceutical composition of any of claims 20-32, or 45, wherein the composition is administered in combination with a second therapeutic agent useful for diminishing an allergic reaction to a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein.

53. Use of the pharmaceutical composition according to claim 52, wherein the second therapeutic agent is selected from a corticosteroid, a bronchial dilator, an antihistamine, epinephrine, a decongestant, another different antibody to Fel d1 and a peptide vaccine.

What is claimed is:

1. An isolated human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, wherein the antibody or antigen-binding fragment thereof comprises the three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) contained within the heavy chain variable region (HCVR) sequence of SEQ ID NO: 18; and the three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) contained within the light chain variable region (LCVR) sequence of SEQ ID NO: 26.

2. The isolated human monoclonal antibody or antigen-binding fragment thereof of claim 1, wherein the human antibody or antigen-binding fragment thereof binds specifically to Fel d1 with a K_D equal to or less than 10^{-6} M, as measured by surface plasmon resonance.

3. An isolated human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, wherein the antibody comprises: (a) the HCVR of SEQ ID NO: 18; and (b) the LCVR of SEQ ID NO: 26.

4. The isolated human monoclonal antibody or antigen-binding fragment thereof of claim 3, wherein the HCVR and LCVR comprise the three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) and the three light chain CDRs (LCDR1, LCDR2 and LCDR3) consisting of:

(a) the HCDR1 domain of SEQ ID NO: 20;
(b) the HCDR2 domain of SEQ ID NO: 22;
(c) the HCDR3 domain of SEQ ID NO: 24;
(d) the LCDR1 domain of SEQ ID NO: 28;
(e) the LCDR2 domain of SEQ ID NO: 30; and
(f) the LCDR3 domain of SEQ ID NO: 32.

5. The isolated human monoclonal antibody or an antigen binding fragment thereof of claim 1, wherein the antibody or fragment thereof interacts with at least one amino acid sequence selected from the group consisting of amino acid residues ranging from position 85 to position 103 of SEQ ID NO: 396; amino acid residues ranging from position 85 to position 104 of SEQ ID NO: 396; and amino acid residues ranging from position 113 to position 127 of SEQ ID NO: 396.

6. The isolated human monoclonal antibody or an antigen binding fragment thereof of claim 1, wherein the antibody or fragment thereof interacts with at least one amino acid sequence selected from the group consisting of SEQ ID NO: 402, 403, and 404.

7. A pharmaceutical composition comprising a therapeutically effective amount of the isolated human monoclonal antibody or an antigen-binding fragment thereof of claim 1 that binds specifically to Fel d1, together with one or more pharmaceutically acceptable excipients.

8. A pharmaceutical composition comprising a therapeutically effective amount of a first isolated human monoclonal antibody, or an antigen-binding fragment thereof that binds specifically to Fel d1, of claim 1; and a second isolated human monoclonal antibody, or an antigen-binding fragment thereof that binds specifically to Fel d1, together with one or more pharmaceutically acceptable excipients.

9. The pharmaceutical composition of claim 8, wherein:

a) the isolated first human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises the HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 18/26; and

b) the isolated second human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, comprises the HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 306/314.

10. A pharmaceutical composition comprising the human antibody or an antigen-binding fragment thereof having the HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 18/26, further comprising three or more isolated human monoclonal antibodies that bind specifically to Fel d1, or antigen-binding fragments thereof, comprising the HCVR/LCVR amino acid sequence pairs selected from the group consisting of SEQ ID NOs: 66/74, 130/138, 306/314 and 162/170.

11. The pharmaceutical composition of claim 9, wherein the isolated second human monoclonal antibody, or an antigen binding fragment thereof, interacts with amino acid residues ranging from position 15 to position 24 of SEQ ID NO: 396.

12. The pharmaceutical composition of claim 9, wherein the isolated second human monoclonal antibody, or an antigen binding fragment thereof, interacts with an amino acid sequence of SEQ ID NO: 412.